News

Under the agreement, the company has purchased ANDAs for 0.5mg, 1mg and 2mg Estradiol Tablets, and 5mg Selegiline Hydrochloride Capsules. The seller’s identity and the financial terms of

Discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland, GBR 1302 is a HER2xCD3 bispecific antibody based on the company’s BEAT antibody technology

The three-year research is aimed at leveraging complementary strengths, expertise and assets to certify and progress new research targets and molecules into clinical development. Spanning from target selection

The latest move comes a day after the death toll of the Ebola outburst reached 1,350. Further, professional teams across the world are being invited to submit research

Under the terms of agreement, Regeneus will provide technology, know-how and research facilities to aid Cryosite in the development of methods for the expansion of cord tissue-derived mesenchymal

Manufactured by Kronus Market Development Associates, ZnT8Ab test can help some type 1 diabetic patients receive timely diagnosis and treatment for their disease. Characterized by failure of insulin

The compound, to be renamed MOR209/ES414, is an anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer, which was developed by Emergent using its proprietary ADAPTIRTM (modular protein technology) platform. Preclinical

Fluticasone furoate inhalation powder has been approved for 100mcg and 200mcg doses. It is controlled through a dry powder inhaler called Ellipta, which has been deployed across a

The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement